Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 3 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 1 1

Interventions

Cyclophosphamide 385 Specimen Handling 371 Magnetic Resonance Spectroscopy 325 Radiotherapy 306 Biopsy 269 Cisplatin 257 Carboplatin 253 Paclitaxel 235 Doxorubicin 226 Fluorouracil 200 Etoposide 197 Vincristine 182 Bevacizumab 180 Filgrastim 170 Gemcitabine 163 Leucovorin 149 Cytarabine 144 aldesleukin 140 Taxes 127 Docetaxel 122 Oxaliplatin 113 Chemotherapy, Adjuvant 113 fludarabine phosphate 111 Rituximab 107 Methotrexate 107 Radiation 106 Bortezomib 105 Prednisone 102 Irinotecan 100 Dexamethasone 100

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Interventional × golimumab × Clear all

NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡